No Data
Guosen: Continuously recommending Innovative Drugs and paying attention to investment opportunities in Medical Devices.
Currently, the Industry is undergoing significant supply-side structural reforms, and the collective procurement of Pharmaceuticals and Medical Devices is also nearing completion, with the expectation of entering a new growth cycle in 2025.
Orient: Initiates a "Buy" rating for Hutchmed (China) (00013) with a Target Price of 33.24 HKD.
Orient predicts that Hutchmed (China) (00013) will have revenue of 680 million, 844 million, and 1 billion dollars for the years 2024-2026 respectively.
【Brokerage Focus】Orient gives Hutchmed (China) (00013) an initial "Buy" rating as innovative products yield results.
Jinwu Finance News | Orient has released a Research Report, initiating coverage of Hutchmed (China) (00013). The company was founded in 2000, and for over twenty years has been deeply engaged in the field of small molecule oncology, with three commercialized products and multiple late-stage clinical drugs, accumulating rich experience in commercial Operation, while partnering with MNCs to explore international markets. CK Hutchison Holdings is the largest Shareholder, and the management team is stable with a strong research and development background. The company's Operation is steady, with a revenue CAGR of 23.1% from 2017 to 2023, and it achieved its first profit of 0.101 billion dollars in 2023. The report indicates that the company's innovative products are entering.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
